Triglyceride lowering interventions
Pro Research Analysisby 
Searched over 200M research papers
Overview of Triglyceride Lowering Interventions
Elevated triglyceride (TG) levels are linked to increased risks of atherosclerotic cardiovascular disease (CVD), hepatic steatosis, and pancreatitis. Multiple interventions—both established and emerging—target TG reduction to improve health outcomes, especially in patients with metabolic disorders and diabetes 1237.
Established Triglyceride-Lowering Therapies
Fibrates, Niacin, and Omega-3 Fatty Acids
Fibrates, niacin, and omega-3 fatty acids (OM3FAs) are traditional TG-lowering agents. Fibrates and niacin have shown inconsistent results in reducing cardiovascular events, especially when used alongside statins, leading to their reduced recommendation in some guidelines 135. Omega-3 fatty acids, particularly high-dose eicosapentaenoic acid (EPA), have demonstrated significant TG reduction and cardiovascular risk reduction in high-risk patients, as seen in the REDUCE-IT trial 358. EPA-only formulations lower TGs without raising LDL cholesterol, while EPA+DHA combinations are also effective but may increase LDL in some cases .
Statins and Combination Therapies
Statins, while primarily targeting LDL cholesterol, also modestly lower TGs and are a cornerstone of CVD risk reduction. Combination therapies with statins and other TG-lowering agents are common, but the incremental benefit for CVD risk reduction remains under investigation 235.
Novel and Emerging Triglyceride-Lowering Agents
RNA-Based and Monoclonal Antibody Therapies
Recent advances include RNA-silencing therapies and monoclonal antibodies targeting key proteins in TG metabolism. Antisense oligonucleotides (ASOs) against apolipoprotein C-III (ApoC-III) and angiopoietin-like protein 3 (ANGPTL3), as well as monoclonal antibodies like evinacumab, have shown effective TG-lowering in clinical trials 12. These agents are promising, especially for patients with severe or refractory hypertriglyceridemia.
Peroxisome Proliferator-Activated Receptor (PPAR) Modulators
Selective PPAR modulators, such as pemafibrate, have demonstrated significant TG reduction but have not shown a reduction in cardiovascular events in large trials, such as PROMINENT 16. Dual PPAR-α/γ and PPAR-α/δ agonists are also under investigation for their potential benefits in TG lowering and metabolic disease management .
GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and liraglutide, significantly lower TGs, especially in patients with obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and polycystic ovary syndrome (PCOS). Semaglutide provides the greatest TG reduction, but gastrointestinal side effects may limit its use. These agents offer dual benefits for lipid and glycemic control, making them valuable for cardiometabolic risk reduction .
Experimental Compounds
New chemical entities, such as tricyclic matrine derivatives, have shown potent TG-lowering effects in preclinical models of NAFLD, primarily by activating the PPARα-CPT1A pathway. These compounds are in early stages of development but represent a novel class of potential anti-NAFLD and TG-lowering agents .
Clinical Outcomes and Considerations
Cardiovascular Risk Reduction
Meta-analyses and systematic reviews indicate that TG-lowering therapy is associated with reduced CVD events and cardiovascular mortality, particularly in patients with diabetes, but not with reduced stroke or all-cause mortality 57. The benefit appears to be independent of age, sex, region, and degree of TG reduction . However, some large trials have failed to show a direct link between TG reduction and major cardiovascular event reduction, especially when background statin therapy is used 46.
Safety and Tolerability
Most TG-lowering agents are well tolerated, but some, like pemafibrate, may increase the risk of adverse renal events and venous thromboembolism, while others, such as GLP-1 RAs, may cause gastrointestinal side effects 69. Individualized therapy is important to balance efficacy and tolerability.
Conclusion
Triglyceride-lowering interventions include established agents like fibrates, niacin, and omega-3 fatty acids, as well as novel therapies such as RNA-based drugs, monoclonal antibodies, PPAR modulators, and GLP-1 receptor agonists. While these interventions effectively lower TG levels, evidence for cardiovascular risk reduction is strongest for high-dose EPA and in specific high-risk populations. Ongoing research will clarify the long-term benefits and optimal use of these therapies, especially in combination with other lipid-lowering agents and in patients with metabolic disorders 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Recent advances in pharmacotherapy for hypertriglyceridemia.
New triglyceride-lowering agents show potential in reducing cardiovascular disease risk, but their effectiveness and safety in preventing diabetes and non-alcoholic fatty liver disease require further clinical trials.
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Targeting triglycerides may improve atherosclerotic cardiovascular disease outcomes, but current evidence is inconsistent.
DOI